Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Vietnamese Women's Health Project III
Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women
Status: Enrolling
Updated:  1/25/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
Vietnamese Women's Health Project III
Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women
Status: Enrolling
Updated: 1/25/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.
Status: Enrolling
Updated:  1/25/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.
Status: Enrolling
Updated: 1/25/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome
Status: Enrolling
Updated:  1/25/2018
Columbia University Medical Center
mi
from
New York, NY
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome
Status: Enrolling
Updated: 1/25/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated:  1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated: 1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
Status: Enrolling
Updated:  1/25/2018
Baystate Medical Center
mi
from
Springfield, MA
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
Status: Enrolling
Updated: 1/25/2018
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2018
Johns Hopkins University
mi
from
Baltimore, MD
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2018
Eastern Cooperative Oncology Group (ECOG) Research Base
mi
from
Brookline, MA
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2018
Eastern Cooperative Oncology Group (ECOG) Research Base
mi
from
Brookline, MA
Click here to add this to my saved trials
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2018
Emory University
mi
from
Atlanta, GA
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2018
Northwestern University
mi
from
Chicago, IL
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Status: Enrolling
Updated:  1/26/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Status: Enrolling
Updated: 1/26/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated:  1/26/2018
Pacific Breast Care Medical Clinic
mi
from
Costa Mesa, CA
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated: 1/26/2018
Pacific Breast Care Medical Clinic
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated:  1/26/2018
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated: 1/26/2018
Beckman Laser Institute University of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated:  1/26/2018
UCSD Regional Fertility Center
mi
from
La Jolla San Diego, CA
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated: 1/26/2018
UCSD Regional Fertility Center
mi
from
La Jolla San Diego, CA
Click here to add this to my saved trials
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated:  1/26/2018
Chao Family Comprehensive Cancer Center, UCIMC
mi
from
Orange, CA
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated: 1/26/2018
Chao Family Comprehensive Cancer Center, UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
La Jolla, CA
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/26/2018
Clinical Research Facility
mi
from
Minneapolis, MN
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/26/2018
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials